Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: The governor, who is also a pediatric neurologist, worked to comfort victims of Friday’s shooting and their families, while helping coordinate the massive government response. He discussed the shooting with President Donald Trump in a private phone call, stood shoulder to shoulder with other elected officials at a news conference and pressed for tighter gun control to national audiences. The subject of widespread mockery after the racist photo from his medical school yearbook surfaced, the Democratic governor appears determined to project that he’s up to the task. “Actions speak a lot louder than words. And I will have the leadership that’s needed,” Northam said in an interview with NPR after the shooting, while discussing potential plans to push for increased gun regulations. Police said 12 people were killed and several others injured when DeWayne Craddock, an engineer with the city’s utilities department, opened fire inside a municipal building Friday afternoon. Northam quickly left Richmond after the shooting and drove to Virginia Beach, speaking to local, state and other officials on the way down to coordinate responses and share information. After a news conference Friday evening, Northam took a call from Trump to discuss the shooting, with the president offering the federal government’s full support. Michael Berlucchi, a Virginia Beach City Council member, praised the governor and other officials for their work to address the shooting’s aftermath from the city’s emergency operations center. “Nobody carried their baggage into that room,” Berlucchi said Sunday. “The only thing I saw was public servants coming together to address the worst tragedy in the history of our city.” On Saturday, Northam attended a vigil at a church where he told those gathered that “God is in control.” He visited a hospital to meet with survivors and thank doctors and staff. In broadcast interviews with national media, Northam stressed the need for action to prevent similar deadly shootings. “We lost 12 lives yesterday. If you look at the commonwealth of Virginia, we lost over 900 lives over the past two years to gun violence, gun-related accidents,” Northam said on CNN. “So I will make decisions in the upcoming days but we need to look at our laws: are they safe, do they keep people protected in the Commonwealth of Virginia?” The governor has long been an advocate for stricter gun control. He made the issue a top priority of his 2017 gubernatorial campaign, drawing from his experience as a pediatrician and Army doctor who has treated children and soldiers wounded by firearms. But a package of bills Northam pushed this year, including legislation to limit gun magazine size and give local governments broader authority to ban guns in city buildings, went nowhere in a staunchly pro-gun Republican-controlled Virginia General Assembly. Northam hinted Saturday in media interviews that he may be considering some kind of executive action related to gun control efforts that would bypass the legislature, but his office declined to say what specific actions he may take. Any dramatic moves by the governor would face stiff resistance from his political opponents. Philip Van Cleave, president of the Virginia Citizens Defense League, said Northam doesn’t have any real power to impose new gun limits and any efforts to do so would be an attempt to deflect attention away his scandal. “He’d be very happy to try and change the focus away from the blackface stuff,” Van Cleave said. Northam has been battling for months to regain a sense of normalcy in office after a picture surfaced in February of man in blackface and another person wearing a Ku Klux Klan outfit on his medical school yearbook page. Northam has denied being in the picture, and investigators recently said they can’t conclusively establish the identities of either person in the 35-year-old photo. The governor withstood widespread pressure for him to resign, which weakened after scandal soon enveloped his potential successors . Two women publicly accused Lt. Gov. Justin Fairfax of sexual assault, which he denies, and Attorney General Mark Herring announced he’d also worn blackface in college, just days after calling on Northam to resign. Both Fairfax and Herring have also resisted calls to resign. Fairfax was also in Virginia Beach after the shooting. He attended a church service Sunday where and pledged to take “serious action” to prevent future mass shootings. “I think that thoughts and prayers from politicians are not enough,” Fairfax said. “We’ve had too many thoughts and prayers over the years and we’ve not acted in the ways to prevent these mass shootings in the future.” ___ This story has been corrected to say pediatrician, not pedestrian. ___ Contributors include Associated Press writer Ben Finley. Claim: Shooting poses Virginia governor’s first test since scandal.

Ex Output:
Virginia Gov. Ralph Northam wasted little time getting to Virginia Beach after a gunman killed a dozen people in a city office building, the first major test of his leadership since a blackface scandal almost forced him from office four months ago.


Ex Input:
Paragraph: "Gov. Andrew M. Cuomo says women in New York state don’t have to worry about new Trump administration rules ending a federal requirement that employers must include birth control coverage in their health insurance plans. The new rules exempt employers from the Obama-era mandate if they have religious or moral reservations to the coverage. But Cuomo said contraception will still be covered in New York state. ""This year, we ensured that whatever happens at the federal level, women in our state will continue to have cost-free access to reproductive health care,"" Cuomo said in a statement. States can set certain insurance standards beyond what the federal government requires. New York state told insurance companies in January they are required to cover birth control and abortion services. That condition still stands, but is Cuomo right that women in New York state are not affected by Trump’s decision? Limits to state regulation State regulations, like the one from January, do not apply to all plans. The state Department of Financial Services regulates everything sold on the state health exchange, called New York State of Health. That includes plans sold to individuals and companies with 100 or fewer employees. The agency says the state’s birth control mandate covers 1.35 million residents in those plans. Health care offered through companies with more than 100 employees is more complicated. Companies that go the traditional route of buying health coverage through an insurance carrier must adhere to the rules. About 2.5 million people in that category are covered by the state’s birth control mandate. But companies that are self-insured, where the employer assumes a large part of the costs, are not regulated by the state, meaning they need not adhere to the state's birth control mandate. About 60 percent of private sector workers in the U.S. who get their health coverage through an employer were enrolled in a self-insured plan in 2015. That’s up from 46 percent in 1996, according to research from the Employee Benefit Research Institute. In New York state, about 54 percent of private sector employees who get health insurance through their employer had a self-insured plan last year, according to the federal Agency for Healthcare Research and Quality. The option is most popular for companies with at least 1,000 employees. Eighty percent of private sector employees at companies that size in New York state are enrolled in a self-insured plan. What about public health insurance? The federal government sets the baseline for what services are covered under Medicaid. Government workers are covered under state regulation, but Medicaid and Medicare enrollees are not.States can add to that list. The list of services covered by Medicaid in New York state goes well beyond the federal standard. New York is one of multiple states where Medicaid covers birth control and abortion services. About a third of the state’s population alone is on Medicaid. Our ruling Cuomo said women in New York state ""will continue to have cost-free access to reproductive health care"" because of an action the state took earlier this year. But not every woman is in an insurance plan regulated by the state. It’s possible a self-insured large employer in New York state could apply for an exemption from the federal birth control mandate. If granted the exemption, the company would not have to provide health coverage for birth control to its employees. Those exemptions are not expected to be widespread, but they are possible. Cuomo’s statement needs clarification." Claim: Women in our state will continue to have cost-free access to reproductive health care

Ex Output:
"Cuomo said women in New York state ""will continue to have cost-free access to reproductive health care"" because of an action the state took earlier this year. But not every woman is in an insurance plan regulated by the state. It’s possible a self-insured large employer in New York state could apply for an exemption from the federal birth control mandate. If granted the exemption, the company would not have to provide health coverage for birth control to its employees. Those exemptions are not expected to be widespread, but they are possible. Cuomo’s statement needs clarification."


Ex Input:
Paragraph: Although the release doesn’t give actual costs of warfarin versus some of the newer drugs, or factor in the cost of the usual monthly blood testing required of those taking the drug, it does note the cost of the gene testing used for the study, and that the $200 price tag is now less than a month’s prescription of one of the newer anti-coagulants on the market. The release gives results in both actual numbers of patients and the percentage of reduction of adverse events in those given the genetic test and a comparison group. Although it does so in general terms, the release covers the essentials: the risk of using blood thinners like warfarin and the risks of not using them. The release offers a good description of the design of the study. It was randomized and enrolled more than 1,600 older patients at high risk of blood clots following surgeries. The release explains that one group received warfarin dosing based on standard factors (age, height and weight) and the second group was dosed using these clinical factors plus their genetic variants. The release also offers a detailed breakdown on how many fewer side effects occurred among patients had genetic testing completed compared to those who didn’t. No mongering here. Nicely done and quite complete. Although the release briefly mentions the availability of a “newer anticoagulant,” it should have included a sentence or two about these newer injectable drugs and their overall risks and benefits in comparison to warfarin. It would also have been helpful to tell readers whether the genetic testing that appears to play a role in safer warfarin dosing would have clinical relevance for informing the use of the new blood thinners as well. The fact is that genetic testing is irrelevant for the newer anti-coagulants because they operate in a completely different manner. But all the blood thinners — old and new — carry the same risk of bleeding. The problem with warfarin is the variability in blood levels which requires frequent monitoring, hence the genetic tests to guide dosing. The careful reader will get it: testing for these genetic variants is still an experimental practice for the most part, and further testing of how the mutations affect warfarin is needed. But the release could have been more explicit in saying that no one is yet recommending genetic testing for millions of warfarin users. While the genetic tests are “available” in the sense that anyone can order them for the most part, they are not routinely used clinically and probably wouldn’t be covered by insurance so in that sense they are not widely available to most people. The release describes how the genetic test used in the new study differs from previous similar studies. Overall the language is careful and contextual. The headline should have been toned back a bit to note that this is early research and more study is needed before concluding that “Genetic testing helps set safe dose of common blood thinner,” as the headline now states. Claim: Genetic testing helps set safe dose of common blood thinner

Ex Output:

This news release describes results of a study designed to learn whether testing for the presence of three gene variants could make dosing with the blood thinner warfarin safer for patients given the drug to prevent blood clots after joint replacement surgery. The study found a modest reduction in the risk of bleeding or clots (from over- or under-dosing) in those whose regimens were developed in part by genetic testing for the variants, compared to those whose doses were calculated without the genetic testing. The release does an overall good job in describing the study, its purpose and design; and in quantifying the results. It could have been even stronger if it had included more information about newer alternatives to warfarin that are growing in use and an explicit statement that no one is yet recommending routine genetic testing for the variants based on this study. And although the headline somewhat over promises clinical benefit at this point in time, thoughtful readers will come away with a decent understanding of the context of the research and its potential impact. Some estimates put the number of Americans regularly taking the clot-preventing blood thinner warfarin and several newer anticoagulants at more than six million. Warfarin (sold under the brand name Coumadin) requires frequent blood testing to address risks of overdoses (and potentially lethal bleeding) and under-dosing (ineffective prevention of strokes and other blood clots). Because warfarin is cheap, and its effects are reversible with vitamin K, research designed to make it easier and safer for patients to take is likely to be highly newsworthy for them and their caregivers.